MKI67 and breast cancer: As expected, patients selected for this strategy were mostly young individuals with higher stage BC and a more aggressive phenotype—mainly luminal B-like (58%) and TNBC (33%)— exhibiting higher baseline Ki67 index levels and/or higher histologic grade.